[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335733-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335733-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","risk-of-incident-cancer-in-veterans-with-diabetes-who-use-metformin-versus-sulfonylureas","Risk of Incident Cancer in Veterans with Diabetes Who Use Metformin Versus Sulfonylureas","","Prior research suggests metformin may have anti-cancer effects, but evidence remains limited. This retrospective cohort study evaluated incident diabetes-related and non-diabetes-related cancers among US veterans aged ≥55 years without cancer at baseline, using incident new-user data from 2001–2012. Cox proportional hazards models with propensity-score matched inverse probability of treatment weighting were applied. Among 88,713 veterans followed for 4.2 years, metformin users showed lower diabetes-related cancer risk versus sulfonylurea users (HR 0.66), with reduced liver, colorectal, and esophageal cancers; no difference was seen for non-diabetes-related cancers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/risk-of-incident-cancer-in-veterans-with-diabetes-who-use-metformin-versus-sulfonylureas/335733/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/risk-of-incident-cancer-in-veterans-with-diabetes-who-use-metformin-versus-sulfonylureas/335733.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study objective regarding diabetes treatment and cancer risk?","Question",{"text":63,"@type":64},"To assess the association between diabetes treatment type (metformin versus sulfonylureas) and incident cancer risk in a cohort of US veterans, focusing on both diabetes-related and non-diabetes-related cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the researchers design the cohort and analysis?",{"text":68,"@type":64},"They used a large retrospective incident new-user cohort of US veterans initiating metformin or sulfonylureas between 2001 and 2012, applying Cox proportional hazards models with propensity score-matched inverse probability of treatment weighting.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main findings comparing metformin with sulfonylureas?",{"text":72,"@type":64},"After adjustment, metformin was associated with a lower risk of incident diabetes-related cancer (HR 0.66) versus sulfonylureas, including lower incidence of liver, colorectal, and esophageal cancers; there was no association for non-diabetes-related cancer (HR 0.96).","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335733,1790015100,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":118,"preview_page_count":4},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Original Article  \n[http://www.jcpjournal.org](http://www.jcpjournal.org)  \npISSN 2288-3649 · eISSN 2288-3657 [https://doi.org/10.15430/JCP.24.012](https://doi.org/10.15430/JCP.24.012)  \nRisk of Incident Cancer in Veterans with Diabetes Who Use Metformin Versus Sulfonylureas  \nMaya M. Abdallah1,*, Beatriz Desanti de Oliveira2,*, Clark DuMontier3,4,5, Ariela R. Orkaby3,4,5, Lisa Nussbaum5, Michael Gaziano4,5, Luc Djousse4,5, David Gagnon5,6, Kelly Cho4,5, Sarah R. Preis6,**, Jane A. Driver3,4,5,**  \n1Section of Hematology/Oncology, Department of Medicine, Boston University School of Medicine, Boston, MA, 2Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, 3New England Geriatrics Research, Education and Clinical Center (GRECC), VA Boston Healthcare System, 4Division of Aging, Brigham and Women’s Hospital, Harvard Medical School, 5Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, 6Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA  \nPrior research suggests metformin has anti-cancer effects, yet data are limited. We examined the association between diabetes treatment (metformin versus sulfonylurea) and risk of incident diabetes-related and non-diabetes-related cancers in US veterans. This retrospective cohort study included US veterans, without cancer, aged ≥ 55 years, who were new users of metformin or sulfonylureas for diabetes between 2001 to 2012. Cox proportional hazards models, with propensity score-matched inverse probability of treatment weighting (IPTW) were constructed. A total of 88,713 veterans (mean age 68.6 ± 7.8 years; 97.7% male; 84. 1% White, 12.6% Black, 3.3% other race) were followed for 4.2 ± 3.0 years. Among metformin users (n = 60,476), there were 858 incident diabetes-related cancers (crude incidence rate [IR; per 1,000 person-years] = 3.4) and 3,533 non-diabetes-related cancers (IR = 14. 1) . Among sulfonylurea users (n = 28,237), there were 675 incident diabetes-related cancers (IR = 5.5) and 2,316 non-diabetes-related cancers (IR = 18.9) . After IPTW adjustment, metformin use was associated with a lower risk of incident diabetes-related cancer (hazard ratio [HR] = 0.66, 95% CI 0.58-0.75) compared to sulfonylurea use. There was no association between treatment group (metformin versus sulfonylurea) and non-diabetes-related cancer (HR = 0.96, 95% CI 0.89-1.02) . Of diabetes-related cancers, metformin users had lower incidence of liver (HR = 0.39, 95% CI 0.28-0.53), colorectal (HR = 0.75, 95% CI 0.62-0.92), and esophageal cancers (HR = 0 .54, 95% CI 0 .36-0.81) . Among US veterans, metformin users had lower incidence of diabetes-related cancer, particularly liver, colorectal, and esophageal cancers, as compared to sulfonylurea users. Use of metformin was not associated with non-diabetes-related cancer. Further studies are needed to understand how metformin use impacts cancer incidence indifferent patient populations.  \nKey Words Metformin, Diabetes mellitus, Neoplasms prevention  \nINTRODUCTION  \nPatients with diabetes mellitus type 2 have an increased risk of several malignancies including pancreatic, hepatic, colorectal, endometrial, ovarian, breast, and bladder cancer [1- 4] . Multiple mechanisms have been hypothesized to explain this association, including a combination of shared risk factors (such as age, obesity, physical inactivity, diet, and alcohol) as well as direct causal effects of metabolic derangement on tumor cell growth [5,6] . There has been growing interest  \nin exploring diabetes medications as prevention or treatment for cancer. Metformin inhibits hepatic gluconeogenesis and reduces insulin resistance in peripheral tissues. It acts primarily by activating AMP-activated protein kinase (AMPK) and modulates numerous downstream pathways associated with cancer risk, including inhibition of mTOR signaling, reduction of protein synthesis, and upregulation of antioxidant genes ","cbCaia3vdbc3VMpv","https://ap.wps.com/l/cbCaia3vdbc3VMpv","pdf",290732,"English","# Introduction\n# Materials and Methods\n## Study population and selection criteria","[{\"question\":\"What was the study objective regarding diabetes treatment and cancer risk?\",\"answer\":\"To assess the association between diabetes treatment type (metformin versus sulfonylureas) and incident cancer risk in a cohort of US veterans, focusing on both diabetes-related and non-diabetes-related cancers.\"},{\"question\":\"How did the researchers design the cohort and analysis?\",\"answer\":\"They used a large retrospective incident new-user cohort of US veterans initiating metformin or sulfonylureas between 2001 and 2012, applying Cox proportional hazards models with propensity score-matched inverse probability of treatment weighting.\"},{\"question\":\"What were the main findings comparing metformin with sulfonylureas?\",\"answer\":\"After adjustment, metformin was associated with a lower risk of incident diabetes-related cancer (HR 0.66) versus sulfonylureas, including lower incidence of liver, colorectal, and esophageal cancers; there was no association for non-diabetes-related cancer (HR 0.96).\"}]","Risk of Incident Cancer in Veterans with Diabetes Who Use Metformin Versus Sulfonylureas | PDF",1790012152]